Companion Diagnostic Collaboration and Licensing Deals 2016-2023
SUMMARY
Companion Diagnostic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023
DESCRIPTION
Companion Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of companion diagnostic deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 181 companion diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of companion diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2016.
Chapter 3 provides an overview of the leading companion diagnostic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostic dealmaking with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of companion diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific companion diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in companion diagnostic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
Companion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.
Companion Diagnostic Collaboration and Licensing Deals includes:
Analyzing contract agreements allows due diligence of:
BENEFITS
Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:
Companion Diagnostic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023
DESCRIPTION
Companion Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of companion diagnostic deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 181 companion diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of companion diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2016.
Chapter 3 provides an overview of the leading companion diagnostic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostic dealmaking with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of companion diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific companion diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in companion diagnostic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse companion diagnostic collaboration and licensing deals
- Benchmark analysis – identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Companion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.
Companion Diagnostic Collaboration and Licensing Deals includes:
- Trends in companion diagnostic dealmaking in the biopharma industry
- Directory of companion diagnostic deal records covering pharmaceutical and biotechnology
- The leading companion diagnostic deals by value
- Most active companion diagnostic licensing dealmakers
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
BENEFITS
Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse precision medicine in oncology collaboration and licensing deals
- Benchmark analysis – identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Executive Summary
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN COMPANION DIAGNOSTIC DEALMAKING
2.1. Introduction
2.2. Companion diagnostic deals over the years
2.3. Most active companion diagnostic dealmakers
2.4. Companion diagnostic deals by deal type
2.5. Companion diagnostic deals by therapy area
2.6. Companion diagnostic deals by industry sector
2.7. Deal terms for companion diagnostic deals
2.7.1 Companion diagnostic deals headline values
2.7.2 Companion diagnostic deal upfront payments
2.7.3 Companion diagnostic deal milestone payments
2.7.4 Companion diagnostic royalty rates
CHAPTER 3 – LEADING COMPANION DIAGNOSTIC DEALS
3.1. Introduction
3.2. Top companion diagnostic deals by value
CHAPTER 4 – MOST ACTIVE COMPANION DIAGNOSTIC DEALMAKERS
4.1. Introduction
4.2. Most active companion diagnostic dealmakers
4.3. Most active companion diagnostic deals company profiles
CHAPTER 5 – COMPANION DIAGNOSTIC CONTRACTS DEALMAKING DIRECTORY
5.1. Introduction
5.2. Companion diagnostic contracts dealmaking directory
CHAPTER 6 – COMPANION DIAGNOSTIC DEALMAKING BY TECHNOLOGY TYPE
Deal directory
Deal directory – Companion diagnostic deals by company A-Z
Deal directory – Companion diagnostic deals by deal type
Deal directory – Companion diagnostic deals by therapy area
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN COMPANION DIAGNOSTIC DEALMAKING
2.1. Introduction
2.2. Companion diagnostic deals over the years
2.3. Most active companion diagnostic dealmakers
2.4. Companion diagnostic deals by deal type
2.5. Companion diagnostic deals by therapy area
2.6. Companion diagnostic deals by industry sector
2.7. Deal terms for companion diagnostic deals
2.7.1 Companion diagnostic deals headline values
2.7.2 Companion diagnostic deal upfront payments
2.7.3 Companion diagnostic deal milestone payments
2.7.4 Companion diagnostic royalty rates
CHAPTER 3 – LEADING COMPANION DIAGNOSTIC DEALS
3.1. Introduction
3.2. Top companion diagnostic deals by value
CHAPTER 4 – MOST ACTIVE COMPANION DIAGNOSTIC DEALMAKERS
4.1. Introduction
4.2. Most active companion diagnostic dealmakers
4.3. Most active companion diagnostic deals company profiles
CHAPTER 5 – COMPANION DIAGNOSTIC CONTRACTS DEALMAKING DIRECTORY
5.1. Introduction
5.2. Companion diagnostic contracts dealmaking directory
CHAPTER 6 – COMPANION DIAGNOSTIC DEALMAKING BY TECHNOLOGY TYPE
Deal directory
Deal directory – Companion diagnostic deals by company A-Z
Deal directory – Companion diagnostic deals by deal type
Deal directory – Companion diagnostic deals by therapy area
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Companion diagnostic deals since 2016
Figure 2: Active companion diagnostic dealmaking activity – 2016 - 2023
Figure 3: Companion diagnostic deals by deal type since 2016
Figure 4: Companion diagnostic deals by therapy area since 2016
Figure 5: Companion diagnostic deals by industry sector since 2016
Figure 6: Companion diagnostic deals with a headline value
Figure 7: Companion diagnostic deals with an upfront value
Figure 8: Companion diagnostic deals with a milestone value
Figure 9: Companion diagnostic deals with a royalty rate value
Figure 10: Top companion diagnostic deals by value since 2016
Figure 11: Most active companion diagnostic dealmakers 2016 - 2023
Figure 12: Companion diagnostic deals by technology type since 2016
Figure 1: Companion diagnostic deals since 2016
Figure 2: Active companion diagnostic dealmaking activity – 2016 - 2023
Figure 3: Companion diagnostic deals by deal type since 2016
Figure 4: Companion diagnostic deals by therapy area since 2016
Figure 5: Companion diagnostic deals by industry sector since 2016
Figure 6: Companion diagnostic deals with a headline value
Figure 7: Companion diagnostic deals with an upfront value
Figure 8: Companion diagnostic deals with a milestone value
Figure 9: Companion diagnostic deals with a royalty rate value
Figure 10: Top companion diagnostic deals by value since 2016
Figure 11: Most active companion diagnostic dealmakers 2016 - 2023
Figure 12: Companion diagnostic deals by technology type since 2016
Companion diagnostics partnering over the years
Companion diagnostics partnering has significantly increased in frequency since 2007, to a peak in 2011.
In 2011, 74 companion diagnostics partnering deals were being reported in a year.
Big pharma companion diagnostics dealmaking activity
Big pharma companies play a minor role in signing deals involving companion diagnostics assets, although interest has been growing in recent years as indicated by the recent acquisition of companion diagnostics company assets.
Companion diagnostics deals by value
The list includes deals irrespective of whether the deal is pure licensing or a multicomponent collaborative R&D deal. In general, multicomponent deals attract the highest value. This is because the subject of the deal is normally focused in the development and commercialization of target compound(s) using a platform technology. As such the revenues contributing to the deal headline value is probably a combination of upfront, milestone and royalty payments as opposed to potential immediate, guaranteed revenues.
Unlike mainstream pharma and biotech partnering, the list is not dominated by bigpharma companies.
The list also suggests that the time for high value companion diagnostics deals has now passed. Whilst this may be true for the present time, it is likely that such deals will return as the development of companion diagnosticss emerges for costly biotech treatments in the next decade.
